The Drug Controller-General of India (DCGI) has granted approval to market Abraxane for injectible suspension in India for the treatment of breast cancer

Biocon Ltd and Abraxis BioScience Inc have announced that the Drug Controller-General of India (DCGI) has granted approval to market Abraxane for injectible suspension in India for the treatment of breast cancer. Commercial introduction of Abraxane in the Indian market is expected in 2008 following the completion of the appropriate importation certifications.

In August 2007, Biocon and Abraxis announced an agreement for the commercialisation of Abraxane in India by Biocon. Under the terms of the agreement, Biocon will have the right to market the drug in India, Pakistan, Bangladesh, Sri Lanka, the UAE, Saudi Arabia, Kuwait and certain other South Asian and Persian Gulf countries. – Our Bureau